Browsing by Author "Icduygu, Fadime Mutlu"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Pubmed An investigation of the effects of FGFR2 and B7-H4 polymorphisms in breast cancer.(2013) Ozgöz, Asuman; Samli, Hale; Oztürk, Kuyaș Hekimler; Orhan, Bülent; Icduygu, Fadime Mutlu; Aktepe, Fatma; Imirzalioglu, NecatPolymorphisms in FGFR2 are important markers for breast cancer susceptibility in the general population. CHEK2 and FGFR2 polymorphisms with known susceptibility alleles of BRCA1, BRCA2, PTEN, and TP53, can be investigated as potential modifiers of high penetrant risk alleles. Although the B7-H4 gene is highly expressed in many different tumors, there is one published study showing the association of polymorphisms with breast cancer. We aimed to investigate FGFR2 and B7-H4 polymorphisms in breast cancer in the Turkish community.Pubmed Expression of , and long non‑coding RNAs in papillary thyroid cancer and its effects on clinicopathological features.(2022-04-01T00:00:00Z) Icduygu, Fadime Mutlu; Akgun, Egemen; Sengul, Demet; Ozgoz, Asuman; Alp, EbruLong non‑coding RNAs (lncRNAs) are molecules that are >200 base pairs long and do not encode a protein. However, they perform important roles in regulating gene expression. Recent studies have revealed that the changes in the expressions of lncRNAs serve a role in the development and metastases of a number of types of cancer. A number of studies have been published on the association of SOX2 overlapping transcript (), differentiation antagonizing non‑protein coding RNA () and tissue differentiation‑induced non‑coding RNA () expression with various types of cancer. However, researchers have not yet studied their roles in papillary thyroid cancer or at least, those roles are not clarified. The aim of the present study was to investigate the expression and clinical significance of , and in papillary thyroid cancer (PTC). A total of 102 patients with PTC were included in the present study. Reverse transcription‑quantitative PCR method was used to determine the relative gene expression levels of lncRNAs and then the relationship between expressions of lncRNAs and clinical characteristics of the subjects was analyzed in detail. Expression levels of (P=0.016) and (P=0.017) increased in the tumor samples in contrast to the normal tissues. No significant difference was observed in the expression level of (P=0.298). In addition, expression was associated with micro carcinoma (P<0.001), tumor size (P=0.010) and primary tumor (P=0.006), while expression was associated with age (P=0.030) and micro carcinoma (P=0.004). The findings of the present study indicated that may contribute to the development of PTC while may contribute to both the development and progression of PTC.